PROGRAMME Poster Presentations
Poster Session 1: Helicobacter 1
Chair: Javier Gisbert, Spain, Yvette Miendje Deyi, Belgium
P01.01.
Bioinformatics and qRT-PCR analysis of miR-155 & predicted target genes in clinical samples of Helicobacter pylori infected endoscopy candidates
Withdrawn
P01.02.
Withdrawn
P01.03.
Evaluation of in vitrobiofilm formation by Helicobacter pylori
Yolanda Moreno, valencia, Spain
P01.04.
Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: a systematic review and meta-analysis
Xinlu Ren, Beijing, China
P01.05.
Incidence of Helicobacter pylori-related peptic ulcer disease have decreased for last 10 years: A multicenter study using a common data model in Korea
Woon Geon Shin, Seoul, Korea, Republic of
P01.06.
The current Japanese prevalence of Helicobacter pylori infection in cholecystic bile
Yoshihisa Fukuda, Fukuoka, Japan
P01.07.
Management of Helicobacter pylori infection in a center from the north-east region of Romania
Elena Popovici, Bacau, Romania
P01.08.
Genomic diversity of gastric/enteric pathogens through high-end computing: Implications for Global Infection Control Priorities
Niyaz Ahmed, Hyderabad, India
P01.09.
H. pylori prevalence is associated with high altitude in a population of dyspeptic patients in Nepal
Michael Trubshaw, Oxford, United Kingdom
P01.10.
Prevalence and severity of gastroesophageal reflux disease in Japan over the past 10 years
Mariko Hojo, Tokyo, Japan
P01.11.
Bismuth-based quadruple therapy for the first-line treatment of clarithromycin-resistant Helicobacter pylori infection: a prospective randomized comparison of 7-day or 14-day treatment duration
Jung-Hwan Oh, Seoul, Korea, Republic of
Poster Session 2: Helicobacter 2
Chair: Sébastien Kindt, Belgium, Ruffin Ntounda, Belgium
P02.01.
Helicobacter pylori found incidentally during upper endoscopy performed for diagnosis of common pediatric gastrointestinal diseases.
Michal Kori, Rehovot, Israel
P02.02.
Pre-clinical validation of NanoPyl®: a bioengineered approach for Helicobacter pylori management
Paula Parreira, Porto, Portugal
P02.03.
Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial
Hong Lu, Shanghai, China
P02.04.
Molecular diagnosis of Helicobacter pylori: validation of Allplex H. pylori and ClariR Assay
Pierre Bogaerts, Yvoir, Belgium
P02.05.
Hippo pathway dysregulation on Helicobacter pylori-related gastric cancer
Yong Chan Lee, Seoul, Korea, Republic of
P02.06.
The Presence of Gastric Auto-antibodies Could be Related with the Re-infection of Helicobacter pylori.
GaGyeong Jeon, Su-won, Korea, Republic of
P02.07.
Ten-year evolution of primary antimicrobial resistance among Helicobacter pylori in Belgium
Te-Din Huang, Yvoir, Belgium
P02.08.
comparison of helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: a randomized, multicenter, non-inferiority study
Samryong Jee, Busan, Korea, Republic of
P02.09.
Trends in the prescription of empirical treatments and their effectiveness in naïve patients over 10 years (2013-2022) in Europe: data from the European Registry on the management of Helicobacter pylori infection (Hp-EuReg).
Olga Nyssen, Madrid, Spain
P02.10.
Clinical evaluation of a novel molecular diagnosis kit based on Qprobe for detecting Helicobacter pylori using stool sample
Momoko Tsuda, Sapporo, Japan
P02.11.
Empirical second-line treatments in Europe: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg).
Olga Nyssen, Madrid, Spain
P02.12.
Helicobacter pylori and non-Helicobacter pylori Helicobacter infection rates showed markedly different associations with upper gastrointestinal diseases among Asian countries
Masahiko Nakamura, Isehara, Japan
P02.13.
European registry on Helicobacter pylori management (Hp-EuReg): analysis of 2,254 empirical rescue therapies on third and subsequent lines.
Olga Nyssen, Madrid, Spain
Poster Session 3: Helicobacter 3
Chair: Colm O'Morain, Ireland, Dulciene Queiroz, Brazil
P03.01.
Sixth-line eradication therapy against Helicobacter pylori infection: preliminary data from the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg).
Olga Nyssen, Madrid, Spain
P03.02.
Helicobacter pylori CagA perturbs non-canonical Wnt/planar cell polarity (PCP) signaling, which mediates lineage specification of epithelial stem cells
Masanori Hatakeyama, Tokyo, Japan
P03.03.
Frequency of Blood group Antigen Binding (bab) genes varies across Helicobacter pylori populations and phylogeny reveal they group following a population structure
Zilia Munoz-Ramirez, Chihuahua, Mexico
P03.04.
Effectiveness of Helicobacter pylori treatments according to antibiotic resistance: results from the European Registry on H. pylori management (Hp-EuReg).
Luis Bujanda, San Sebastián, Spain
P03.05.
Index of gastric epitheliocytes proliferation in Helicobacter pylori-positive patients with atrophic gastritis depending on the presence of complete or incomplete intestinal metaplasia
Vladislav Tsukanov, Krasnoyarsk, Russian Federation
P03.06.
Experience with single-capsule bismuth quadruple therapy in 8,000 patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Olga Nyssen, Madrid, Spain
P03.07.
Index of gastric epitheliocytes apoptosis in Helicobacter pylori-positive patients with atrophic gastritis depending on the presence of high or low degree dysplasia
Vladislav Tsukanov, Krasnoyarsk, Russian Federation
P03.08.
Clinical phenotypes through machine learning of first-line treated patients during the period 2013-2022: data from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Olga Nyssen, Madrid, Spain
P03.09.
The protection of tissueresident memory T cells during Helicobacter pylori infection
Ruolan Gong, Munich, Germany
P03.10.
The role of mitochondrial modulation in innate immunity and tumorigenesis during Helicobacter pylori infection
Mohamed Tarek Badr, Freiburg, Germany
P03.11.
EFFECT OF HELICOBACTER PYLORI TREATMENT ON RECURRENCE OF UPPER GASTROINTESTINAL BLEEDING IN ATRIAL FIBRILLATION PATIENTS WITH ANTITHROMBOTIC AGENTS
Beom Jin Kim, Seoul, Korea, Republic of
P03.12.
Neutrophil migration in response to exposure of Helicobacter pylori outer membrane vesicles in a polarized gastric epithelial cell model
JUNG MOGG KIM, Seoul, Korea, Republic of
Poster Session 4: Helicobacter 4
Chair: Peter Malfertheiner, Germany, Theodore Rokkas, Greece
P04.01.
Efficacy of culture-based tailored therapy as primary treatment of Helicobacter pylori infection: a multicenter prospective study
Jeong Hoon Lee, Seoul, Korea, Republic of
P04.02.
Prevalence of Helicobacter pylori infection among gastroenterologists and gastroendoscopists in Brazil
Luiz Coelho, Belo Horizonte, Brazil
P04.03.
The impact of co-infectious rate of clarithromycin-susceptible and resistant H. pylori strains for the efficacy of eradication treatment including clarithromycin
Mototsugu Kato, Sapporo, Japan
P04.04.
usefulness of texture and color enhancement imaging in the evaluation of endoscopic findings of gastritis
Shotaro Oki, Tokyo, Japan
P04.05.
Assessment of risk factors for a positive 13С-urea breath test in Ukrainian population
Sergii Melashchenko, Vinnytsya, Ukraine
P04.06.
Brazilian Registry on H. pylori management (Hp-BrazilReg): analysis of 640 first-line treatments
Luiz Coelho, Belo Horizonte, Brazil
P04.07.
Time trends and effectiveness of bismuth treatment for Helicobacter pylori infection: Results from the European registry on Helicobacter pylori management (Hp-EuReg) during 2013-2021
Xavier Calvet, Sabadell, Spain
P04.08.
Controlof Helicobacter pylori by CD8+ T cells is mediated by the recognition of CagA
Maximilian Koch, München, Germany
P04.09.
Long-term effect of Helicobacter pylori therapy on atrophic gastritis and intestinal metaplasia after endoscopic resection of gastric neoplasm: a follow-up of a randomized controlled trial
Jong Yeul Lee, Goyang, Korea, Republic of
P04.10.
Comparison of Four Diagnostic Tests for Helicobacter pylori Infection
Doron Boltin, Petah Tikva, Israel
P04.11.
Empirical therapy vs. tailored therapy of H. pylori in Korea: A nationwide placebo-controlled study in Korea
Byung-Wook Kim, Incheon, Korea, Republic of
Poster Session 5: Helicobacter 5
Chair: Jan Bornschein, United Kingdom, Juozas Kupcinskas, Lithuania
P05.01.
The eradication rates of concomitant and tailored therapy were higher than sequential and triple with probiotics and triple therapy for Helicobacter pylori
YoungKyeong Nam, Seoul, Korea, Republic of
P05.02.
Excellent eradication rate of 14-day once-daily vonoprazan, levofloxacin, clarithromycin-MR, and bismuth for H. pylori infection in high clarithromycin resistance area: A Prospective Randomized Study (ONCE-VONO trial)
Ratha-korn Vilaichone, Pathumthani, Thailand
P05.03.
Molecular testing guided therapy versus susceptibility testing guided therapy in first-line and third-line Helicobacter pylori eradication- Two multicentre, open-label, randomised controlled, non-inferiority trials
Jyh-Ming Liou, Taipei, Taiwan
P05.04.
Effectiveness of levofloxacin-containing rescue therapy in central Seoul, Korea
Jeong Seop Moon, Seoul, Korea, Republic of
P05.05.
The art of deceiving: lipid-based decoys for Helicobacter pylori infection management
Ana Pinho, Porto, Portugal
P05.06.
Role of proton pump inhibitors dosage in the effectiveness of Helicobacter pylori eradication treatments: results from the European Registry on H. pylori management (Hp-EuReg).
Olga P. Nyssen, Madrid, Spain
P05.07.
Evaluation of molecular-based clarithromycin resistance testing in Helicobacter pylori compared to culture-based testing.
Stephen Molloy, Dublin24, Ireland
P05.08.
The role of nanostructured lipid carriers (NLC) protein corona in H. pylori selectivity
Rute Chitas, Porto, Portugal
P05.09.
PPI’s effectiveness in H. Pylori eradication schemes depends on the basal secretion of hydrochloric acid
Iryna Paliy, Vinnytsya, Ukraine
P05.10.
Watch out Helicobacter: chitosan nanoparticles decorated with antimicrobial peptides for gastric infection
Diana R. Fonseca, Porto, Portugal
P05.11.
Biopsies sampling in Helicobacter pylori negative patients: is it still worthy?
Giulia Fiorini, Bologna, Italy
Poster Session 6: Helicobacter 6
Chair: Emilie Bessède, France, Christian Schulz, Germany
P06.01.
Impact of sub-inhibitory concentrations of antibiotics on the biofilm development of Helicobacter pylori
Paweł Krzyżek, Wroclaw, Poland
P06.02.
Molecular evolution of the 16S rRNA gene within the Helicobacter pylori Genome Project
Roxana Zamudio, Norwich, United Kingdom
P06.03.
Withdrawn
P06.04.
practical adequacy of the 7-day triple regimen for Helicobacter pylori eradication according to the clarithromycin resistance-associated mutation PCR results: A single centered retrospective study
Dae Young Cheung, Seoul, Korea, Republic of
P06.05.
The role of Helicobacter suis, Fusobacterium gastrosuis and the pars oesophageal microbiota in gastric ulceration in slaughter pigs receiving meal or pelleted feed
Emily Taillieu, Merelbeke, Belgium
P06.06.
Presence of potentially novel Helicobacter pylori-like organisms in gastric samples from cats and dogs
Emily Taillieu, Merelbeke, Belgium
P06.07.
Evaluation of a New Liquid Type Rapid Urease Test Kit for Diagnosis of Helicobacter pylori
Hannah Lee, Incheon, Korea, Republic of
P06.08.
Efficacy and tolerability of bismuth-based eradication therapy without proton pump inhibitors for Helicobacter pylori infection in patients with corpus atrophic gastritis: a retrospective single-center experience
Emanuele Dilaghi, Rome, Italy
P06.09.
Enhancing the Therapeutic Potential of Resveratrol Against Helicobacter pylori Infections through Chitosan Nanoparticles
Larissa Spósito, Araraquara, Brazil
P06.10.
Prevalence of Helicobacter pylori infection in preschool children benefiting from Education and Nutrition Centers and Children's Centers for Nutrition and Comprehensive Care (CEN-CINAI) nutritional programs in Costa Rica (2014-2016)
Vanessa Ramírez-Mayorga, Mercedes, Costa Rica
P06.11.
Helicobacter pylori protein SabB promotes colonization and adherence to metaplastic stomach tissue
Jacob Frick, Seattle, United States
P06.12.
Early-life Helicobacter pylori infection worsens metabolic state in mice on high fat diet
Sigri Kløve, Copenhagen, Denmark
Poster Session 7: Cancer 1
Chair: Ari Ristimäki, Finland, Herbert Tilg, Austria
P07.01.
The influence of procedural volume on the outcome of endoscopic submucosal dissection for gastric neoplasm: a nationwide population-based study using administrative data
Jae Gyu Kim, Seoul, Korea, Republic of
P07.02.
Endoscopic Histoacryl injection for esophagojejunostomy leakage after total gastrectomy in patients with gastric cancer
seok choi, Busan, Korea, Republic of
P07.03.
Investigation of gastric cancer in the cases of autoimmune gastritis.
Shoko Ono, Sapporo, Japan
P07.04.
treatment outcome and safety of gastric endoscopic submucosal dissection in our hospital
Yukako Shoji, Sugukita,
Fukuoka, Japan
P07.05.
Volatilomic signatures of gastric juice: investigation of potential volatile markers of gastric cancer and H. pylori infection
Daria Slefarska-Wolak, Kielce, Poland
P07.06.
Is it necessary to obtain biopsy from the incisura angularis for staging of atrophic gastritis according to the OLGA protocol?
Sergey Khomeriki, Moscow, Russian Federation
P07.07.
An Artificially Intelligent Diagnostic Assistant for gastric inflammation (AIDA)
Javier Gisbert, Madrid, Spain
P07.08.
Serologic test in metachronous tumors after endoscpic resection for gastric neoplasm
Sung Woo Jung, Ansan, Korea, Republic of
P07.09.
PREDICTIVE FACTORS ASSOCIATED WITH OVERALL SURVIVAL RATE IN FEMALE GASTRIC CANCER PATIENTS: A LARGE POPULATION-BASED STUDY IN THE ASSOCIATION OF SOUTHEAST ASIAN NATIONS (FGC-ASEAN TRIAL)
Ratha-korn Vilaichone, Pathumthani, Thailand
P07.10.
Gastric microbiome inhibits the development of premalignant lesions and gastric cancer
Ki Taek Nam, Seoul, Korea, Republic of
P07.11.
Helicobacter pylori and colon cancer - from epidemiologic association to mechanistic insights
Markus Gerhard, München, Germany
P07.12.
predictive value of combined risk score for gastric cancer
Valli De Re, Aviano, Italy
Poster Session 8: Cancer 2
Chair: Steffen Backert, Germany, José Machado, Portugal
P08.01.
Lung microbiota composition change in non-small cell lung cancer
Rokas Lukosevicius, Kaunas, Lithuania
P08.02.
Novel serum biomarkers for early detection of gastric cancer and gastric preneoplastic lesions
Christian Schulz, Muenchen, Germany
P08.03.
Classification of gastric adenocarcinomas according to Lauren in reference centers in Central Brazil.
Monica Barbosa, Goiania, Brazil
P08.04.
Antioxidant protection in stomach cancer
Aleksandr Sinyakov, Krasnoyarsk, Russian Federation
P08.05.
Physical and biochemical nuclear signatures: a secret message underlying gastric cancer invasion
Joana Figueiredo, Porto, Portugal
P08.06.
Dairy product consumption and gastric adenocarcinoma: is there an association?
Monica Barbosa, Goiania, Brazil
P08.07.
Influence of Helicobacter pylori infection on Bacteroides fragilis-induced intestinal carcinogenesis in C57BL/6 Apcmin/+ Mice
Zhongming Ge, Cambridge, United States
P08.08.
Epidemiological profile of gastric cancer in the Central region of Brazil: is there a difference between sex?
Monica Barbosa, Goiania, Brazil
P08.09.
Histological characteristics and sociodemograficamente profile of pacientes with gastric adenocarcinomas in reference hospitals in Brazil
Monica Barbosa, Goiania, Brazil
P08.10.
Impact of the COVID-19 pandemic on hospital mortality from gastric cancer in Brazil
Monica Barbosa, Goiania, Brazil
P08.11.
Gastric cancer mortality in different geographic regions of Brazil
Monica Barbosa, Goiania, Brazil
Poster Session 9: Cancer 3
Chair: Constanza Camargo, USA, Marcis Leja, Latvia
P09.01.
Early retirement pensioners diagnosed with stomach or esophagus cancer in Germany - characterization and utilization of medical rehabilitation.
Maria Weyermann, Krefeld, Germany
P09.02.
Effect of Helicobacter pylori eradication on gastric cancer prevention in Korea-a randomized controlled clinical trial (HELPER)- baseline results
Jin Young PARK, Lyon, France
P09.03.
H. pylori infection affects the HER2-CDH1 interaction
Mariateresa Casarotto, Aviano, Italy
P09.04.
Proprotein convertases inhibition as a new strategy to target Cancer Stem Cells properties in Gastric Cancer
Christine Varon, Bordeaux, France
P09.05.
Withdrawn
P09.06.
Improving the accuracy of the pepsinogen test in detecting precancerous gastric lesions by adjusting cut-off values in current smokers by the presence of Helicobacter pylori infection
Danute Razuka-Ebela, Riga, Latvia
P09.07.
Small intestinal bacterial overgrowth SIBO in patients with upper gastrointestinal cancer: prevalence and impact on quality of life
Rosa Rosania, Magdeburg, Germany
P09.08.
Impact of Helicobacter pylori on immunotherapy versus molecular targeted therapy in hepatocellular carcinoma: a multicenter, retrospective study
Christian Schulz, München, Germany
P09.09.
Next generation phage display mimotope-variation analysis (MVA)-defined antibody response patterns link breast cancer to Helicobacter pylori infection
Helle Sadam, Tallinn, Estonia
P09.10.
Helicobacter pylori attachment-blocking antibodies protect against gastric disease
Thomas Boren, Umea, Sweden
P09.11.
Metachronous Recurrence among Patients who received Endoscopic Resection for Early Gastric Cancer at age ≤ 50 years: compared Patients with > 50 years
Jong-Jae Park, Korea, Japan
Poster Session 10: Helicobacter 7
Chair: Nele Brusselaers, Belgium, Marie Joossens, Belgium
P10.01.
Withdrawn
P10.02.
Withdrawn
P10.03.
Identifying macrolide exposure using Drug Utilization Review system and its relation to clarithromycin resistance
Kee Don Choi, Seoul, Korea, Republic of
P10.04.
The high-dose dual therapy is effective as a first-line treatment for Helicobacter pylori in Mongolia
Byambajav Tsogt_Ochir, Ulaanbaatar, Mongolia
P10.05.
Inhibitory effects of commensal gastrointestinal bacteria on Helicobacter pylori
Johannes Westphal, Munich, Germany
P10.06.
Influence of probiotics use on the safety of helicobacter pylori treatments: results of the European registry on the management of helicobacter pylori infection (Hp-EuReg)
Olga Nyssen, Madrid, Spain
P10.07.
Prescription pattern of probiotics as an adjuvant therapy for helicobacter pylori therapy: results of the European registry on the management of helicobacter pylori infection (Hp-EuReg)
Olga Nyssen, Madrid, Spain
P10.08.
Role of probiotics in the effectiveness of treatment against Helicobacter pylori: results of the European registry on the management of helicobacter pylori infection (Hp-EuReg)
Olga Nyssen, Madrid, Spain
P10.09.
Diagnostic value of eight commercial tests for the rapid detection of Helicobacter pylori antigen in stool.
Véronique Miendje Deyi, Brussels, Belgium
P10.10.
Investigation of PMSS1 Helicobacter pylori virulence factors responsible for human to mouse transmission
Jeong Heon Cha, Seoul, Korea, Republic of
P10.11.
Immunoglobulin for chronic gastritis
Aleksandr Sinyakov, Krasnoyarsk, Russian Federation
P10.12.
A consolidated pipeline for generating reference-quality PacBio Helicobacter pylori genome assemblies and methylation profiles
WEN LUO, Rockville, United States
P10.13.
Association between Helicobacter pylori infection and diabetes mellitus: a cross-sectional study in the Central Brazil Region
Monica Barbosa, Goiania, Brazil
P10.14.
Assessing prophage impact on Helicobacter pylori biofilm formation
Filipa Vale, Lisboa, Portugal
P10.15.
In vitro screening of natural and small molecules compounds as potential Helicobacter pylori inhibitors
Filipa Vale, Lisboa, Portugal
Poster Session 11: Helicobacter 8
Chair: Josbert Keller, The Netherlands, Yaron Niv, Israel
P11.01.
Prevalence of Helicobacter pylori cagA gene varies by race among individuals undergoing upper endoscopy
Meira Epplein, Durham, United States
P11.02.
Status of Helicobacter pylori and the location of gastric cancer in a population in the Central Brazil region
Monica Barbosa, Goiania, Brazil
P11.03.
Genome-wide metabolic pathways in Helicobacter pylori populations
Maria Camargo, Rockville, United States
P11.04.
A multicentre survey of Helicobacter pylori antimicrobial resistance in Ireland
Thomas Butler, Dublin, Ireland
P11.05.
Protein-Ligand docking and in vitroscreening as a tool to identify lead hit compounds targeting the key survival Purine Nucleoside Phosphorylase (PNP) enzyme of Helicobacter pylori
Thomas Butler, Dublin, Ireland
P11.06.
CagY a protein regulating Cag pathogenicity island has evolved to mirror human populations and rearrangements in the gene may be associated with disease
Javier Torres, CD Mexico, Mexico
P11.07.
Autophagy influences inflammation in Helicobacter pylori-related gastric carcinogenesis
Isidora Simovic, Kensington, Australia
P11.08.
The accuracy of a new 13C urea breath test meal (REFEX) for patients with dyspepsia and GERD taking proton pump inhibitors
Sitke Aygen, Cologne, Germany
P11.09.
Geographic variation in Helicobacter pylori vacA sequences: amplification of vacA copy number and loss of intact ORFs through multiple mechanisms
Patricio Gonzalez-Hormazabal, Santiago, Chile
P11.10.
Helicobacter pylori plasmid detection and assembly: major challenges
Kristine Jones, Rockville, United States
P11.11.
Helicobacter pylori infection induces MMP-3 and MMP-9 expression via MAPK pathways
Dionyssios Sgouras, Athens, Greece
P11.12.
Helicobacter pylori infection, pepsinogens, and serum ghrelin concentrations for the assessment of gastric pathology
Paula Mantero, Buenos Aires, Argentina
P11.13.
Clinical course and outcome of patients with drug allergy related to Helicobacter pylori eradication
Sung Eun Kim, Busan, Korea, Republic of
P11.14.
Isolation and characterization of Helicobacter species and identification of two novel Helicobacter spp. in marine mammals
Zeli Shen, Cambridge, United States
P11.15.
Culture-based antimicrobial resistance of Helicobacter pylori in Busan, South Korea
Sung Eun Kim, Busan, Korea, Republic of
Poster Session 12: Helicobacter 9
Chair: Thomas Boren, Sweden, Massimo Rugge, Italy
P12.01.
Epidemiological study of the Helicobacter pylori prevalence in Moscow: first results
Dmitriy Bordin, Moscow, Russian Federation
P12.02.
Species classification of Enterohepatic Helicobacter species isolated from Old World non-human primates
James Fox, Cambridge, United States
P12.03.
Enterohepatic Helicobacter species isolated from New World non-human primates and lemurs
Zeli Shen, Cambridge, United States
P12.04.
Azobenzenesulfonamides as selective carbonic anhydrase inhibitors: an innovative strategy against H. pylori infection
Beatrice Marinacci, Chieti, Italy
P12.05.
Genomic determinants of antibiotic resistance in Helicobacter pylori treatment and surveillance
Francisco Martínez-Martínez, Valencia, Spain
P12.06.
A whole genome sequencing for searching genetic determinants of clarithromycin resistance in Russian Helicobacter pylori clinical isolates
Daria Starkova, St. Petersburg, Russian Federation
P12.07.
The prevalence of Helicobacter pylori infection in the Slovenian Southeast region using two stool antigen tests
Samo Jeverica, Novo mesto, Slovenia
P12.08.
Clarithromycin primary resistance in the Slovenian coastal region determined by PCR and culture-based methods, 2022-2023
Samo Jeverica, Novo mesto, Slovenia
P12.09.
Low accuracy and limited diagnostic information of urease test from gastric biopsies limit its utility for rapid exclusion of Helicobacter pylori infection during endoscopy
Samo Jeverica, Novo mesto, Slovenia
P12.10.
Regional differences in the management of Helicobacter pylori infection in Spain: data from the European Registry on H. pylori management (Hp-EuReg).
Olga Nyssen, Madrid, Spain
P12.11.
Determinants of virulence of Helicobacter pylori clinical isolates in Russia
Nikita Gladyshev, St.Petersburg, Russian Federation
P12.12.
Bioinformatic analysis reveals completed prophage genomes within admixed Helicobacter pylori populations originating from Cabo Verde.
Ebony Cave, Leicester, United Kingdom
P12.13.
Efficacy of Helicobacter pylori eradication treatment in obese patients undergoing bariatric surgery
Paula Mantero, Buenos Aires, Argentina
P12.14.
Deciphering gastric cancer susceptibility through multi-population genome-wide association analysis within the Helicobacter pylori Genome Project
Difei Wang, Rockville, United States
P12.15.
Role of Family Members and Source of Water in Transmission of Helicobacter pylori Infection in a Libyan Rural Region.
Abdurrazag Nami, Tripoli, Libyan Arab Jamahiriya
Poster Session 13: Helicobacter 10
Chair: Alexander Link, Germany, Sinead Smith, Ireland
P13.01.
Semi-quantitative assessment of Helicobacter pylori by rapid urease tests in pediatrics
Yulia Gaykova, St.Petersburg, Russian Federation
P13.02.
Prevalence and antibiotic susceptibility of Campylobacter in Ethiopian children with diarrhoea and domestic animals
Wondemagegn Mulu, Ghent, Belgium
P13.03.
Assessing the validity of helicobacter pylori detection methods in community-driven research
HaoHung Dang, Vancouver, Canada
P13.04.
The contribution of Helicobacter pylori infection to the formation comorbid IBS phenotype
Maria Livzan, Omsk, Russian Federation
P13.05.
Helicobacter pylori infection in patients with autoimmune gastritis: incidence and pathomorphism of the disease
Maria Livzan, Omsk, Russian Federation
P13.06.
NOD1 regulates gastric acidity and favours bacterial persistence during chronic Helicobacter pylori infection in mice
Richard Ferrero, Melbourne, Australia
P13.07.
Helicobacter pylori induces strain-specific pathological alterations in infected hepatocytes
Pirjo Spuul, Tallinn, Estonia
P13.08.
Elucidating the reasons for Helicobacter pylori eradication failure - antibiotic resistance and coexistence of H. pylori with Candida species
Ana Bačić, Belgrade, Serbia
P13.09.
Prevalence changes of Helicobacter pylori infection in dyspeptic patients in Romania
Radu Farcas, Cluj-Napoca, Romania
P13.10.
Bacillary-coccoid transformation activity of Helicobacter pylori in the antrum and body of the stomach
Nikita Gladyshev, St.Petersburg, Russian Federation
P13.11.
Mycobacterium bovis BCG increase the selected determinants of macrophage activity, which were diminished in response to gastric pathogen Helicobacter pylori
Weronika Gonciarz, Lódz, Poland
P13.12.
Salvia cadmica Boiss. extracts modulate activity of macrophages primed with lipopolysaccharide of gastric pathogen Helicobacter pylori
Weronika Gonciarz, Lódz, Poland
P13.13.
Stereocomplexed microparticles loaded with Salvia cadmica Boiss. extracts for enhancement of immune response towards Helicobacter pylori
Weronika Gonciarz, Lódz, Poland
P13.14.
Comparative analysis of Helicobacter pylori strains isolated from Estonia in 2020-2022
Liisa Truu, Tallinn, Estonia
Poster Session 14: Helicobacter 11
Chair: David Graham, USA, Jan Tack, Belgium
P14.01.
Anti‐CagA in Helicobacter pylori‐infected patients with Dyspepsia in South of Libya
Abdurrazag Nami, Tripoli, Libyan Arab Jamahiriya
P14.02.
First description of the data from the Latin American Registry on the Management of Helicobacter pylori Infection (Hp-LATAMReg).
Diego Reyes Placencia, Santiago, Chile
P14.03.
Community-driven bacterial genomics research: antimicrobial resistance and virulence of Helicobacter pylori strains from Arctic Indigenous communities in Canada
Lauren Lindsey, Edmonton, Canada
P14.04.
Trends in macrolide use and prevalence of Helicobacter pylori clarithromycin resistance in Hungary
Gábor Lotz, Budapest, Hungary
P14.05.
Efficacy of Standard Triple Therapy for Helicobacter pylori Eradication in Libyan Dyspeptic Patients: Multicenter Experience Study
Abdurrazag Nami, Tripoli, Libyan Arab Jamahiriya
P14.06.
Associations of NSAID use with Helicobacter pylori density and dyspepsia symptoms in Canadian Arctic Indigenous communities
Rabail Shahid, Edmonton, Canada
P14.07.
Efficacy of standard triple therapy in Helicobacter Pylori infection: a single centre Irish experience
Hilal Shah, Clane, Ireland
P14.08.
The frequency of detection of serological markers of atrophy in respondents from an epidemiological study of the prevalence of Helicobacter pylori infection in Moscow: first results
Dmitriy Bordin, Moscow, Russian Federation
P14.09.
Community-driven investigation of environmental sources of H. pylori infection in Indigenous communities in Northern Canada
Lorelei Baquiran, Edmonton, Canada
P14.10.
Real-time assessment of pH by Endofaster, any advantages to the clinical practice?
André Trigo, Coimbra, Portugal
P14.11.
Tackling antibiotic resistance of Helicobacter pylori: a multilayered problem
Vladimir Milivojevic, Belgrade, Serbia
P14.12.
The efficacy and safety of vonoprazan in dual/triple/quadruple regimens both in first-line and rescue therapy for Helicobacter Pylori eradication: a systematic review with meta-analysis
Belén Martínez Benito, Madrid, Spain
P14.13.
Effectiveness & safety of high dose dual therapy: a single centre experience
Conor Costigan, Dublin, Ireland
P14.14.
Association between alcohol, tobacco and cagA and vacA positive Helicobacter pylori infection in individuals with gastropathies in Brazil
Monica Barbosa, Goiania, Brazil
P14.15.
Prevalence of resistance Helicobacter pylori to clarithromycin in patients with rheumatoid arthritis after COVID-2019
Valeriy Kryvy, Simferopol, Russian Federation
P14.16.
Timing of helicobacter eradication in patients with peptic ulcer does not affect success rate
Yu Jin Kim, Seoul, Korea, Republic of
Poster Session 15: Microbiota 1
Chair: Gianluca Ianiro, Italy, Mirjana Rajilić-Stojanović, Serbia
P15.01.
Standardisation of Microbiome Research with the NFDI4Microbiota
Sarah Schulz, Heidelberg, Germany
P15.02.
Alteration of gut microbiota in ulcerative colitis
Ruta Inciuraite, Kaunas, Lithuania
P15.03.
Effect of oral Bifidobacterium breve on facial skin: A randomized double-blind placebo-controlled study
Yuriko Nishikawa, Tokyo, Japan
P15.04.
Mucin-microbiome signatures shape the tumor microenvironment in gastric cancer
Wout Arras, Antwerp, Belgium
P15.05.
Faecal transplantation for irritable bowel syndrome patients:increasing the dose of the transplant improves the response of males and patients with moderate symptoms
Magdy El-Salhy, Bergen, Norway
P15.06.
The impact of H. pylori eradication regimens on gut microbiome taxonomic distribution and resistome
Olga Sjomina, Riga, Latvia
P15.07.
Increasing correlation in the microbiota compositions of saliva, gastric juice, and gastric tissue during gastric carcinogenesis
Jae-Gyu Kim, Seoul, Korea, Republic of
P15.08.
Colorectal surgery and anastomotic insufficiency are associated with mucosal microbiome alterations
Konrad Lehr, Magdeburg, Germany
P15.09.
Assessment of the microbiome of biliary stents in patients with obstructive biliary disease
Konrad Lehr, Magdeburg, Germany
P15.10.
The influence of healing earth on the gastrointestinal microbiome of IBS-patients
Sarah Krikonas, Munich, Germany
Poster Session 16: Microbiota 2
Chair: Georgina Hold, Australia, Mario D'Elios, Italy
P16.01.
Withdrawn
P16.02.
Microbiome profile of colorectal cancer patients' gut mucosa and blood plasma samples
Darja Nikitina, Kaunas, Lithuania
P16.03.
Is gut microbiota characterization an effective tool in IBD diagnostics?
Christina Casén, Oslo, Norway
P16.04.
Gastric candida infection
Adriana Barrios, Quetzaltenango, Guatemala
P16.05.
Use of the invertebrate model Galleria mellonella larvae for Helicobacter pylori infection: impact on larvae microbiota
Filipa Vale, Lisboa, Portugal
P16.06.
Gut microbiota and liver cirrhosis
Mila Kovacheva-Slavova, Sofia, Bulgaria
P16.07.
Characterization of the microbiome in low microbial biomass samples with metatranscriptomics
Ceu Figueiredo, Porto, Portugal
P16.08.
Gastric cancer metabolite profiling reveals the presence of compounds with carcinogenic potential
Rui Ferreira, Porto, Portugal
P16.09.
Gut microbiota profile of patients with type 2 diabetes mellitus
Dilyara Safina, Kazan, Russian Federation
Poster Session 17: Microbiota 3
Chair: Benedicte De Winter, Belgium, Francesco Franceschi, Italy
P17.01.
Prevalence of TORCH infections in infants with cholestatic jaundice admitted to a children’s hospital in southern Viet Nam
Thanh Duong Thi, Ho Chi Minh, Viet Nam
P17.02.
Mutual interplay of the gut microbiota composition and diet
Dilyara Safina, Kazan, Russian Federation
P17.03.
Postbiotic metabolites as intestinal barrier protectors during Helicobacter pylori eradication therapy
Leonid Lazebnik, Moscow, Russian Federation
P17.04.
Metagenomic analysis of the changes of infant faecal microbiota after introduction of different food items.
Madara Runge, Riga, Latvia
P17.05.
Altered gastrointestinal homeostasis and microbiota composition in a mouse model for psychiatric disorders.
Kinga Réka Tasnády, Diepenbeek, Belgium
P17.06.
Unraveling the microbial odyssey: navigating the microbiota-gut-vagina axis in women with endometriosis in the Isala project
Inas Rahou, Wilrijk, Belgium
P17.07.
Fine-scale mapping of the vaginal microbiome and its influencing factors
Sarah Ahannach, Antwerp, Belgium
P17.08.
Features of the small intestinal bacterial overgrowth prevalence against the background of lactase deficiency
Valeriy Kryvy, Simferopol, Russian Federation
P17.09.
Understanding the Influence of Donor Liver Microbiome on Recipient Outcomes in Liver Transplantation: A Study on the Role of the Biliary Microbiome
Anella Tomasevic, Munich, Germany